Delirium and Cognitive Impairment Development in Hospitalized Older Adults Under Isolation Conditions
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Aug 3, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether older adults in the hospital who need to be kept in isolation—because of drug-resistant bacteria or other reasons—are more likely to experience delirium (a sudden confusion) or a decline in thinking abilities compared to similar patients who are not isolated. The study will carefully compare patients of the same age, gender, health conditions, and frailty to see if isolation itself affects their mental state.
To take part, patients need to be 70 years or older, currently in the hospital, and under isolation precautions for at least one day. People who are very sick with a life expectancy of less than two weeks, or those in intensive care, cannot join. Participants will have their mental status checked twice daily while in the hospital using a simple screening tool, and their thinking skills will be tested again six weeks after leaving the hospital. The study will last from the time a patient joins until six weeks after they go home. This research aims to better understand how isolation might impact the brain health of older adults during and after their hospital stay.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: - hospitalized patients
- • under isolation precautions for at least 24h
- • 70 years and above
- • Exclusion Criteria: - no informed consent
- • intensive care treatment
- • life expectancy 14 days or less
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Cynthia Olotu, Dr., MD
Principal Investigator
University Medical Centre Hamburg, Department of Anaesthesiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported